{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:10Z","timestamp":1790720350235,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2005,7,15]],"date-time":"2005-07-15T00:00:00Z","timestamp":1121385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1007\/s00259-005-1877-x","type":"journal-article","created":{"date-parts":[[2005,7,14]],"date-time":"2005-07-14T12:27:19Z","timestamp":1121344039000},"page":"1288-1295","source":"Crossref","is-referenced-by-count":52,"title":["111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy"],"prefix":"10.1007","volume":"32","author":[{"given":"Astrid","family":"Capello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Krenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Reubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wout","family":"Breeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,7,15]]},"reference":[{"key":"1877_CR1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0166-2236(93)90050-V","volume":"16","author":"GI Bell","year":"1993","unstructured":"Bell GI, Reisine T. Molecular biology of somatostatin receptors. Trends Neurosci 1993;16:34\u20138","journal-title":"Trends Neurosci"},{"key":"1877_CR2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1006\/bbrc.1993.2122","volume":"195","author":"Y Yamada","year":"1993","unstructured":"Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, et al. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun 1993;195:844\u201352","journal-title":"Biochem Biophys Res Commun"},{"key":"1877_CR3","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1172\/JCI117090","volume":"93","author":"A Kubota","year":"1994","unstructured":"Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994;93:1321\u20135","journal-title":"J Clin Invest"},{"key":"1877_CR4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0306-4522(95)00072-Q","volume":"67","author":"T Reisine","year":"1995","unstructured":"Reisine T, Bell GI. Molecular properties of somatostatin receptors. Neuroscience 1995;67:777\u201390","journal-title":"Neuroscience"},{"key":"1877_CR5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0026-0495(96)90076-1","volume":"45","author":"YC Patel","year":"1996","unstructured":"Patel YC, Greenwood M, Panetta R, Hukovic N, Grigorakis S, Robertson LA, et al. Molecular biology of somatostatin receptor subtypes. Metabolism 1996;45:31\u20138","journal-title":"Metabolism"},{"key":"1877_CR6","first-page":"437","volume":"58","author":"M Jong de","year":"1998","unstructured":"de Jong M, Breeman WA, Bakker WH, Kooij PP, Bernard BF, Hofland LJ, et al. Comparison of 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437\u201341","journal-title":"Cancer Res"},{"key":"1877_CR7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","volume":"20","author":"EP Krenning","year":"1993","unstructured":"Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993;20:716\u201331","journal-title":"Eur J Nucl Med"},{"key":"1877_CR8","first-page":"1","volume-title":"Nuclear medicine annual","author":"EP Krenning","year":"1995","unstructured":"Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. In: Freeman LM, editor. Nuclear medicine annual. New York: Raven Press; 1995. p. 1\u201350"},{"key":"1877_CR9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/09553007514550991","volume":"28","author":"KG Hofer","year":"1975","unstructured":"Hofer KG, Harris CR, Smith JM. Radiotoxicity of intracellular 67Ga, 125I and 3H. Nuclear versus cytoplasmic radiation effects in murine L1210 leukaemia. Int J Radiat Biol Relat Stud Phys Chem Med 1975;28:225\u201341","journal-title":"Int J Radiat Biol Relat Stud Phys Chem Med"},{"key":"1877_CR10","first-page":"3244","volume":"39","author":"RF Martin","year":"1979","unstructured":"Martin RF, Bradley TR, Hodgson GS. Cytotoxicity of an 125I-labeled DNA-binding compound that induces double-stranded DNA breaks. Cancer Res 1979;39:3244\u20137","journal-title":"Cancer Res"},{"key":"1877_CR11","first-page":"98","volume":"44","author":"A Capello","year":"2003","unstructured":"Capello A, Krenning EP, Breeman WA, Bernard BF, de Jong M. Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide. J Nucl Med 2003;44:98\u2013104","journal-title":"J Nucl Med"},{"key":"1877_CR12","first-page":"1519","volume":"37","author":"M Fjalling","year":"1996","unstructured":"Fjalling M, Andersson P, Forssell-Aronsson E, Gretarsdottir J, Johansson V, Tisell LE, et al. Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. J Nucl Med 1996;37:1519\u201321","journal-title":"J Nucl Med"},{"key":"1877_CR13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00003072-199903000-00031","volume":"24","author":"KE McCarthy","year":"1999","unstructured":"McCarthy KE, Lemen L, Espenan G, Woltering EA, Nelson J, Cronin M, et al. Dose-escalation of indium-111 pentetreotide (SomatotherTM): toxicity and clinical response. Clin Nucl Med 1999;24:213","journal-title":"Clin Nucl Med"},{"key":"1877_CR14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","volume":"32","author":"R Valkema","year":"2002","unstructured":"Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [In- DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110\u201322","journal-title":"Semin Nucl Med"},{"key":"1877_CR15","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<767::AID-IJC17>3.0.CO;2-T","volume":"81","author":"GD Slooter","year":"1999","unstructured":"Slooter GD, Breeman WA, Marquet RL, Krenning EP, van Eijck CH. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer 1999;81:767\u201371","journal-title":"Int J Cancer"},{"key":"1877_CR16","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/0024-3205(91)90053-E","volume":"49","author":"WH Bakker","year":"1991","unstructured":"Bakker WH, Krenning EP, Reubi JC, Breeman WA, Setyono-Han B, de Jong M, et al. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991;49:1593\u2013601","journal-title":"Life Sci"},{"key":"1877_CR17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00944177","volume":"10","author":"S Green","year":"1992","unstructured":"Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239\u201353","journal-title":"Invest New Drugs"},{"key":"1877_CR18","first-page":"149","volume":"41","author":"MG Stabin","year":"2000","unstructured":"Stabin MG, Konijnenberg MW. Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. J Nucl Med 2000;41:149\u201360","journal-title":"J Nucl Med"},{"key":"1877_CR19","first-page":"1260","volume":"45","author":"MW Konijnenberg","year":"2004","unstructured":"Konijnenberg MW, Bijster M, Krenning EP, De Jong M. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with 90Y, 111In, or 177Lu. J Nucl Med 2004;45:1260\u20139","journal-title":"J Nucl Med"},{"key":"1877_CR20","first-page":"2002","volume":"37","author":"P Andersson","year":"1996","unstructured":"Andersson P, Forssell-Aronsson E, Johanson V, Wangberg B, Nilsson O, Fjalling M, et al. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide. J Nucl Med 1996;37:2002\u20136","journal-title":"J Nucl Med"},{"key":"1877_CR21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00006231-199803000-00013","volume":"19","author":"M Jong De","year":"1998","unstructured":"De Jong M, Bernard BF, De Bruin E, Van Gameren A, Bakker WH, Visser TJ, et al. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 1998;19:283\u20138","journal-title":"Nucl Med Commun"},{"key":"1877_CR22","first-page":"659","volume":"57","author":"JR Duncan","year":"1997","unstructured":"Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 1997;57:659\u201371","journal-title":"Cancer Res"},{"key":"1877_CR23","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s002590050439","volume":"26","author":"M Jong de","year":"1999","unstructured":"de Jong M, Breeman WA, Bernard BF, van Gameren A, de Bruin E, Bakker WH, et al. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med 1999;26:693\u20138","journal-title":"Eur J Nucl Med"},{"key":"1877_CR24","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/1097-0215(20010601)92:5<628::AID-IJC1244>3.0.CO;2-L","volume":"92","author":"M Jong de","year":"2001","unstructured":"de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, et al. [177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628\u201333","journal-title":"Int J Cancer"},{"key":"1877_CR25","first-page":"1841","volume":"42","author":"M Jong de","year":"2001","unstructured":"de Jong M, Breeman WA, Bernard BF, Bakker WH, Visser TJ, Kooij PP, et al. Tumor response after [90Y-DOTA0,Tyr3]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001;42:1841\u20136","journal-title":"J Nucl Med"},{"key":"1877_CR26","first-page":"1902","volume":"36","author":"JA O\u2019Donoghue","year":"1995","unstructured":"O\u2019Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902\u20139","journal-title":"J Nucl Med"},{"key":"1877_CR27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.bioeng.1.1.241","volume":"1","author":"RK Jain","year":"1999","unstructured":"Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999;1:241\u201363","journal-title":"Annu Rev Biomed Eng"},{"key":"1877_CR28","doi-asserted-by":"crossref","first-page":"S218","DOI":"10.1007\/s00259-003-1178-1","volume":"30","author":"M B\u00e9h\u00e9","year":"2003","unstructured":"B\u00e9h\u00e9 M, P\u00fcsken M, Henzel M, Gross M, Reitz I, Engelhart-Cabillic E, et al. Upregulation of gastrin and somatostatin receptor after irradiation. Eur J Nucl Med Mol Imaging 2003;30:S218","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1877_CR29","first-page":"S237","volume":"31","author":"M B\u00e9h\u00e9","year":"2004","unstructured":"B\u00e9h\u00e9 M, Koller S, P\u00fcsken M, Gross M, Alfke H, Keil B, et al. Irradiation-induced upregulation of somatostatin and gastrin receptors in vitro and in vivo. Eur J Nucl Med Mol Imaging 2004;31:S237\u20138","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-005-1877-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-005-1877-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-005-1877-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T15:58:52Z","timestamp":1558713532000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-005-1877-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,15]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["1877"],"URL":"https:\/\/doi.org\/10.1007\/s00259-005-1877-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,15]]}}}